Advertisement

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement

Mar

21

Today In Oncology

FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma

Hypofractionated Locoregional RT in Early Breast Cancer

Melanoma-Specific Survival With Sentinel Lymph Node Biopsy

Breast Cancer Ultrasensitive ctDNA Assay Findings and Outcomes After Neoadjuvant Therapy

AMA Survey Finds Rapid Growth in Physician AI Adoption

Advertisement

© 2026 HSP News Service, L.L.C.